4D Molecular Therapeutics (NASDAQ:FDMT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?

4D Molecular Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • FDMT fell below its 200-day moving average of $11.09, trading as low as $10.54 before last changing hands at $10.79.
  • Analyst sentiment remains broadly positive: the consensus rating is Moderate Buy, with an average price target of $30.22, though one analyst rated the stock a Sell.
  • Quarterly EPS of ($1.08) missed estimates of ($1.05), while revenue of $4.14 million slightly exceeded forecasts of $4.13 million.
  • MarketBeat previews top five stocks to own in December.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $11.09 and traded as low as $10.54. 4D Molecular Therapeutics shares last traded at $10.79, with a volume of 814,018 shares traded.

Analysts Set New Price Targets

FDMT has been the topic of a number of recent analyst reports. Bank of America boosted their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a "buy" rating in a research note on Tuesday, September 29th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 target price for the company in a research report on Monday, September 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $30.22.

Read Our Latest Stock Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Trading Down 4.4%

The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.06. The business's fifty day simple moving average is $12.99 and its two-hundred day simple moving average is $11.09. The stock has a market capitalization of $608.34 million, a P/E ratio of -4.00 and a beta of 2.92.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.03). The company had revenue of $4.14 million during the quarter, compared to analyst estimates of $4.13 million. 4D Molecular Therapeutics had a negative return on equity of 47.06% and a negative net margin of 208.57%. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.18 earnings per share for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the sale, the insider directly owned 709,153 shares of the company's stock, valued at $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 120,520 shares of company stock valued at $1,615,978 in the last three months. 7.90% of the stock is currently owned by company insiders.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently modified their holdings of the company. Jupiter Topco LLC bought a new position in 4D Molecular Therapeutics in the second quarter worth $76,466,000. BlackRock Inc. acquired a new stake in 4D Molecular Therapeutics during the second quarter worth $60,463,000. Janus Henderson Group PLC boosted its stake in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock worth $48,868,000 after buying an additional 611,276 shares in the last quarter. Trails Edge Capital Partners LP bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $29,631,296. Finally, Bank of America Corp DE bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $14,905,000. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company's proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?

Before you consider 4D Molecular Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.

While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines